HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.